Skip to content
RDL Network logo
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial — Michael S. Hofman (2021) | RDL Network